Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsORALGeneric

FARYDAK

PANOBINOSTAT LACTATE

Standard Dose
EQ 10MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued

Key Takeaways

  • Primary indication: Review priority: STANDARD Marketing status: Discontinued
  • Approval overview FARYDAK is listed in Drugs@FDA under application 205353 (NDA).
  • Review priority: STANDARD Marketing status: Discontinued Active ingredient PANOBINOSTAT LACTATE Form and strength CAPSULE;ORAL - EQ 10MG BASE Sponsor SECURA Submission history Latest submission status date: 2016-06-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview FARYDAK is listed in Drugs@FDA under application 205353 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PANOBINOSTAT LACTATE Form and strength CAPSULE;ORAL - EQ 10MG BASE Sponsor SECURA Submission history Latest submission status date: 2016-06-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.